Close

Boosting Innovation And Value In UK Biopharma And Medtech

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Green Chemistry in EU Shapes Pharmaceutical Intermediates

Green chemistry is a cutting-edge scientific discipline that focuses...

New recommendations from Imperial College London aim to boost competitiveness in the UK’s biopharma and Medtech sectors. It assesses the value-added per capita in these sectors and provides insights into their needs, challenges, and opportunities. Technological solutions and policy recommendations are identified as crucial for increasing innovation and value-added. It emphasizes the need for collaboration between industry, academia, and the government.

Findings from Imperial College London highlight a slowdown in the UK’s economic growth rate due to declining innovation and competitiveness in key sectors. Sector-based policies are seen as a solution to address the country’s productivity problem, requiring targeted support in research and development, skills, and finance.

Common themes for increasing competitiveness include creating innovative regulatory environments aligned with key markets, anticipating digital technology advancements, and raising innovation productivity through targeted policies and new business models.

The UK’s biopharma sector faces concerns about global competitiveness despite its significant contribution to the economy. The dominance of small and medium-sized enterprises (SMEs) and challenges in clinical trials, regulatory divergence, and slower access to medicines are highlighted.

In the Medtech sector, promising growth is observed, but uncertainties surrounding post-Brexit medical device regulation pose challenges. Recommendations include improving the regulatory environment, increasing sector-specific funding, offering regulatory training, and enhancing technology transfer policies.

To compete globally, the UK needs targeted policies and support for accelerated growth in these sectors. An integrated national life sciences R&D ecosystem is identified as a government objective to support drug discovery, clinical development, and healthcare integration, reducing development cycles and costs, and attracting investments.

Latest stories

Related stories

Buyout of SpringWorks Brings Back Merck KGaA in the M&A Game

Merck KGaA’s long-standing courtship of SpringWorks Therapeutics has finally...

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

Green Chemistry in EU Shapes Pharmaceutical Intermediates

Green chemistry is a cutting-edge scientific discipline that focuses...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back